Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 4NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 8Sarcoma 5Neoplasms 4Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 3Recurrence 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Lymphatic Diseases 2Hematologic Diseases 2Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms by Histologic Type 1Liposarcoma 1Leiomyosarcoma 1Immune System Diseases 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Bone Neoplasms 1B-Cell Malignancies 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × Ifosfamide × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡